Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing.

Sally Lawrence,Farah Faytrouni,Rachel E Harris,Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke,Vikki Garrick,Lee Curtis,Lisa Gervais,Rachel Tayler, Marliss Riou,Richard Hansen,Kevan Jacobson,Richard K Russell

Journal of pediatric gastroenterology and nutrition（2022）

引用 3|浏览6

暂无评分

摘要

Standard infliximab induction resulted in less favorable long-term outcomes for pediatric IBD patients. Optimizing induction using clinical, biomarker, and proactive trough levels resulted in higher post-induction trough levels and a greater odds of attaining long-term clinical remission.

查看译文

关键词

inflammatory bowel disease, therapeutic drug monitoring, treat to target

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要